Reuters logo
2 years ago
BRIEF-Basilea Pharmaceutica: ceftobiprole receives QIDP designation from FDA for treatment of lung and skin infections
August 12, 2015 / 5:38 AM / 2 years ago

BRIEF-Basilea Pharmaceutica: ceftobiprole receives QIDP designation from FDA for treatment of lung and skin infections

Aug 12 (Reuters) - Basilea Pharmaceutica AG :

* Basilea Pharmaceutica AG reports that ceftobiprole received Qualified Infectious Disease Product (QIDP) designation from U.S. FDA for the treatment of lung and skin infections Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below